Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
Velocity is a new cycling event that benefits the Herbert Irving Comprehensive Cancer Center at CUIMC. Columbia riders share why they joined the cause.
Researchers discovered a mechanism that reprograms tumor cells in patients with advanced prostate cancer, reducing their response to anti-androgen therapy.
Based on new evidence, laparoscopic surgery should be offered to most women with early-stage endometrial cancer, says Columbia’s gynecologic cancer chief.
The drug, developed by Columbia and MSK researchers, selectively kills cancer cells and has shown activity against multiple malignancies in pre-clinical studies.